These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36042588)

  • 1. Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia.
    Lee JC; Joung KH; Kim JM; Kang SM; Kim HJ; Ku BJ
    Medicine (Baltimore); 2022 Aug; 101(34):e30287. PubMed ID: 36042588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus.
    Han JH; Joung KH; Lee JC; Kim OS; Choung S; Kim JM; Kang YE; Yi HS; Lee JH; Ku BJ; Kim HJ
    Diabetes Metab J; 2024 Jan; 48(1):112-121. PubMed ID: 38173371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).
    Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Rhee MY; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HS
    Cardiovasc Ther; 2016 Oct; 34(5):371-82. PubMed ID: 27506635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Ju SH; Lim JY; Song M; Kim JM; Kang YE; Yi HS; Joung KH; Lee JH; Kim HJ; Ku BJ
    Front Endocrinol (Lausanne); 2024; 15():1336357. PubMed ID: 38586464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.
    Lee SA; Kim W; Hong TJ; Ahn Y; Kim MH; Hong SJ; Kim BS; Kim SY; Chae IH; Kim BJ; Rhee MY; Shin JH; Kang TS; Cho JM; Kim JS; Lee CW
    Clin Ther; 2021 Sep; 43(9):1573-1589. PubMed ID: 34429197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia.
    Lee JC; Kim JM; Joung KH; Kang SM; Kim HJ; Ku BJ
    J Int Med Res; 2022 Mar; 50(3):3000605221085079. PubMed ID: 35301888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy.
    Rhee MY; Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HY; Kim HS
    Clin Ther; 2019 Dec; 41(12):2571-2592. PubMed ID: 31727361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.
    Strilchuk L; Tocci G; Fogacci F; Cicero AFG
    Expert Opin Pharmacother; 2020 Apr; 21(5):531-539. PubMed ID: 32036729
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
    Lamb YN
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):381-392. PubMed ID: 32648167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
    Moon JS; Park IR; Kim SS; Kim HS; Kim NH; Kim SG; Ko SH; Lee JH; Lee I; Lee BK; Won KC
    Diabetes Metab J; 2023 Nov; 47(6):818-825. PubMed ID: 38043782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol.
    Ju SH; Ku BJ
    Medicine (Baltimore); 2022 Nov; 101(47):e31691. PubMed ID: 36451471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.
    Bando Y; Toyama H; Kanehara H; Hisada A; Okafuji K; Toya D; Tanaka N
    Diabetes Res Clin Pract; 2016 Jan; 111():66-73. PubMed ID: 26589368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia.
    Boutari C; Karagiannis A; Athyros VG
    Expert Rev Cardiovasc Ther; 2021 Jul; 19(7):575-580. PubMed ID: 34102931
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.